CompletedPhase 2NCT03409432
Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma
Studying Lymphomatoid papulosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- John Reneau
- Principal Investigator
- John Reneau, MD, M.DOhio State University Comprehensive Cancer Center
- Intervention
- Brentuximab Vedotin(drug)
- Enrollment
- 26 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2025
Study locations (1)
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03409432 on ClinicalTrials.govOther trials for Lymphomatoid papulosis
Additional recruiting or active studies for the same condition.